SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep
2017 - 2016 - 2015 - 2014

August 2017 Scleroderma News

Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis. Genentech has completed enrollment for a Phase III clinical trial investigating the use of Actemra (tocilizumab) in patients with systemic sclerosis. The aim of the study is to assess the efficacy and safety of Actemra compared to placebo for the treatment of systemic sclerosis. ClinicalTrials.gov, 07/25/2017. (Also see Clinical Trials)

American Medical Association Adding Cytori’s Cell–Based Therapy for Scleroderma Hand Problems to Key Database. The American Medical Association is adding descriptions of Cytori Therapeutics’ cell–based therapy for scleroderma of the hands to its authoritative database of medical procedures, services and technology. Scleroderma News, 07/11/2017. (Also see Clinical Trials)

Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSC). Mechanistically, adipsin might represent a pathogenic link between adipocyte dysfunction and complement pathway activation, and play an important role in the pathogenesis of SSc–PAH. PubMed, Arthritis Rheumatol, 06/26/2017. (Also see Causes of Pulmonary Hypertension)

Galectin’s Candidate Therapy GR-MD-02 Patent Extended to Cover Several Illnesses Including Systemic Sclerosis. The U.S. Patent and Trademark Office has granted Galectin Therapeutics a new patent that extends coverage of its candidate therapy GR-MD-02 to treat systemic sclerosis. Scleroderma News, 06/27/2017. (Also see Clinical Trials)

Pulmonary arterial hypertension (PAH) in scleroderma (SSc): care gaps in screening. Screening for PAH in SSc allows for earlier detection and treatment that prolongs survival and improves symptoms. BioMed Central, Arthritis Research & Therapy, 201719:128. (Also see Pulmonary Hypertension Diagnosis)

The "myth" of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? We suggest the loss of angiogenesis should not be considered as an overall "myth" characterizing systemic sclerosis, but as a very late event of the vascular pathogenesis. PubMed, Arthritis Res Ther, 2017 Jul 6;19(1):162. (Also see Vascular Involvement)

Limited cutaneous systemic sclerosis (lcSSc) skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. Our study suggests the presence of molecular subsets in lcSSc based on gene expression profiling of biopsies from uninvolved skin. PubMed, Arthritis Res Ther, 2017 Jul 4;19(1):156. (Also see Genetics)

The role of microRNA-5196 in the pathogenesis of systemic sclerosis (SSc). These results suggest that microRNA-5196 can be used as a potential biomarker characterising SSc. PubMed, Eur J Clin Invest, 06/21/2017. (Also see Prognosis and Mortality)

Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis (SSc). Our findings emphasize the need to consider right heart catheterisation in selected early SSc patients with pulmonary hypertension suspicion (PH), to clearly determine the cause of PH. PubMed, Clin Exp Rheumatol, 06/20/2017. (Also see Pulmonary Hypertension Diagnosis)

Case Report: Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis. Sildenafil and Bosentan combined therapy was associated in our case with an improvement of the maximum walking distance without adverse effect. PMC, Medicine (Baltimore), 2017 Jun; 96(25): e6988. (Also see Treatments for Pulmonary Arterial Hypertension)

Phototherapy in systemic sclerosis: review. Most studies reported that psoralen plus UVA (PUVA) and UVA1 phototherapy improved clinical outcomes vis-à-vis skin sclerosis, joint mobility, ulcers, and histopathology. PubMed, Photodermatol Photoimmunol Photomed, 07/13/2017. (Also see Morphea Scleroderma Treatments)

Go to Scleroderma Medical News: July 2017
 
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including memorials for
Jim Miller, Arlene Marie Petulla, Frances Maude Baldwin Watson and Rubye Mai Blocker Westmoreland.
Thanks to Winn Schillberg for donating to scleroderma research.
Donate or Shop Now
 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!

Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.